- Home
- ANAB vs RGR Comparison
ANAB vs RGR Comparison
Compare ANAB & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- RGR
- Stock Information
- Founded
- ANAB 2005
- RGR 1949
- Country
- ANAB United States
- RGR United States
- Employees
- ANAB N/A
- RGR N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- RGR Ordnance And Accessories
- Sector
- ANAB Health Care
- RGR Industrials
- Exchange
- ANAB Nasdaq
- RGR Nasdaq
- Market Cap
- ANAB 759.5M
- RGR 627.3M
- IPO Year
- ANAB 2017
- RGR N/A
- Fundamental
- Price
- ANAB $18.59
- RGR $39.29
- Analyst Decision
- ANAB Buy
- RGR
- Analyst Count
- ANAB 10
- RGR 0
- Target Price
- ANAB $36.38
- RGR N/A
- AVG Volume (30 Days)
- ANAB 892.6K
- RGR 135.4K
- Earning Date
- ANAB 05-08-2025
- RGR 05-06-2025
- Dividend Yield
- ANAB N/A
- RGR 1.78%
- EPS Growth
- ANAB N/A
- RGR N/A
- EPS
- ANAB N/A
- RGR 1.77
- Revenue
- ANAB $91,280,000.00
- RGR $535,643,000.00
- Revenue This Year
- ANAB N/A
- RGR $4.74
- Revenue Next Year
- ANAB $59.43
- RGR N/A
- P/E Ratio
- ANAB N/A
- RGR $22.28
- Revenue Growth
- ANAB 432.03
- RGR N/A
- 52 Week Low
- ANAB $12.21
- RGR $34.11
- 52 Week High
- ANAB $41.31
- RGR $48.20
- Technical
- Relative Strength Index (RSI)
- ANAB 57.06
- RGR 50.84
- Support Level
- ANAB $17.50
- RGR $39.28
- Resistance Level
- ANAB $19.60
- RGR $40.14
- Average True Range (ATR)
- ANAB 1.37
- RGR 0.61
- MACD
- ANAB 0.20
- RGR -0.19
- Stochastic Oscillator
- ANAB 60.56
- RGR 15.74
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About RGR Sturm Ruger & Company Inc.
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The Company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.